Drug intelligence / Profile preview

IC 333

Development stage: Preclinical
Lead developer: Iacta Pharmaceuticals
Administration: Ophthalmic

Overview

IC 333 is a preclinical-stage therapeutic candidate under development by Iacta Pharmaceuticals for the treatment of dry eye disease. As of the latest company pipeline updates, the specific mechanism of action, molecular target, and modality (e.g., small molecule or biologic) for IC 333 have not been publicly disclosed. The asset is part of Iacta's specialized portfolio of ophthalmic treatments, which aims to address unmet needs in ocular surface and anterior segment diseases through various pharmacological approaches.

Beyond the preview

Go deeper on IC 333.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IC 333.

Explore the full profile